Eli Lilly to Acquire SiteOne Therapeutics for Up to USD 1 Billion
US-based pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) announced plans to acquire compatriot biotech...
Eli Lilly
Eli Lilly’s Kisunla Approved in Australia for Alzheimer’s Treatment
The Australian Therapeutic Goods Administration (TGA) this week approved Eli Lilly and Company’s (NYSE: LLY)...
Innovent Biologics Commences Phase III GLORY-3 Study of Mazdutide for Metabolic Dysfunction-associated Fatty Liver Disease
China-based Innovent Biologics, Inc. (HKG: 1801) announced the first patient dosing in the Phase III...
Rznomics and Eli Lilly Collaborate on RNA-Editing Therapies for Sensorineural Hearing Loss
South Korea-based RNA-based therapeutics specialist Rznomics Inc. has entered into a strategic global research collaboration...
Eli Lilly and Purdue Expand Partnership With $250 Million Investment
US-based Eli Lilly & Co. (NYSE: LLY) and Purdue University have expanded their long-term partnership...
Alchemab Therapeutics Licenses ATLX-1282 to Eli Lilly for ALS Treatment
UK-based biotech Alchemab Therapeutics Ltd entered into a licensing agreement with US major Eli Lilly...
Eli Lilly Reports 45% YOY Sales Growth in Q1 2025, Driven by Mounjaro and Zepbound
US-based Eli Lilly & Co. (NYSE: LLY) released its Q1 2025 financial report, revealing sales...
Eli Lilly Partners with Creyon Bio to Develop RNA-Targeted Therapies
Eli Lilly and Company (NYSE: LLY) announced a strategic collaboration with Creyon Bio, Inc., a...
United InnoMed Closes RMB 100 Million Series B+ Funding for Heart Failure Devices
Shanghai-based United InnoMed, a developer of Class III active implantable medical devices, has closed a...
Eli Lilly’s Orforglipron Meets Primary Endpoint in Phase III ACHIEVE-1 Trial for Type 2 Diabetes
U.S. pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has announced positive top-line results from...
Eli Lilly Collaborates with BigHat Biosciences to Engineer Advanced Therapeutic Antibodies
US pharmaceutical major Eli Lilly and Company (NYSE: LLY) has entered into a collaboration with...
Eli Lilly Secures Global License for Sangamo’s STAC-BBB Gene Therapy Technology
US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has entered into a licensing agreement...
EMA’s CHMP Issues Negative Opinion on Lilly’s Kisunla for Alzheimer’s
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Eli Lilly Launches Kisunla in China for Early Alzheimer’s Treatment
US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has officially launched Kisunla (donanemab) in...
Laekna Submits Revised Protocol for LAE102 Obesity Trial with Eli Lilly
Sino-US biotech Laekna Therapeutics (HKG: 2105) announced the submission of a revised clinical protocol to...
Eli Lilly Launches Lilly Gateway Laboratory in China to Boost Biotech Innovation
US major Eli Lilly & Co., (NYSE: LLY) has announced the opening of the Lilly...
NovoCare Pharmacy Offers Reduced-Cost Wegovy for Cash-Paying Patients
Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced the launch of NovoCare Pharmacy, a direct-to-patient...
Boehringer Ingelheim Appeals CNIPA’s Invalidation of Jardiance Patents
The Intellectual Property Court of the Supreme People’s Court of China issued a notice, holding...
Magnet Biomedicine and Eli Lilly Partner on Molecular Glue Therapeutics
US-based molecular glue specialist Magnet Biomedicine has entered into a collaboration and license agreement with...
Eli Lilly to Establish Four New US Pharma Manufacturing Sites
US major Eli Lilly & Co. (NYSE: LLY) announced plans to establish four new pharmaceutical...